FDA

FDA issues warning about counterfeit Ozempic in U.S. supply chain

April 14, 2025

FDA has issued a warning about counterfeit semaglutide (Ozempic) found in the U.S. drug supply chain. Several hundred units of the counterfeit product, labeled with lot number NAR0074 and serial number 430834149057, have been seized. The counterfeit products may include non-sterile needles, increasing the risk of infection for patients. FDA has received six adverse event reports related to this lot, but none appear to be linked to the counterfeit product. Novo Nordisk reported all six incidents.

Healthcare providers are advised to check their supplies and report any counterfeit products. Patients should only obtain Ozempic through state-licensed pharmacies and verify the authenticity of their medication. FDA is working with Novo Nordisk to identify and remove counterfeit products from the market.

Source:

(April 14, 2025). FDA. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain